Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simona Soverini

Showing results (91-100 of 162) with videos related to

Pageof 17
Sort By:
Clinical Biochemistry|January 24, 2012
Four-channel asymmetric Real-Time PCR hybridization probe assay: a rapid pre-screening method for critical BCR-ABL kinase domain mutationsJordi Martinez-Serra, Antonio Gutiérrez, Toni F Marcús, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phaseTimothy Hughes, Giuseppe Saglio, Susan Branford, et al.
Leukemia & Lymphoma|November 6, 2012
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms WorkshopRichard A Van Etten, Michael Mauro, Jerald P Radich, et al.
Haematologica|January 19, 2007
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working PartyGianantonio Rosti, Ilaria Iacobucci, Simona Bassi, et al.
Oncotarget|March 17, 2016
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patientsSimona Soverini, Caterina De Benedittis, Katerina Machova Polakova, et al.
Clinical and Translational Medicine|April 25, 2025
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid LeukemiaManuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 25, 2024
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National NetworkMassimo Breccia, Rosalba Cucci, Giovanni Marsili, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular responseFrancesca Palandri, Ilaria Iacobucci, Simona Soverini, et al.
Leukemia Research|January 14, 2015
The impact of sensitive KIT D816V detection on recognition of indolent Systemic MastocytosisGiovanna De Matteis, Roberta Zanotti, Sabrina Colarossi, et al.
Hematological Oncology|May 8, 2021
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplantCristina Papayannidis, Chiara Sartor, Alida Dominietto, et al.
Pageof 17

Showing results (91-100 of 162) with videos related to

Sort By:
Pageof 17
Clinical Biochemistry|January 24, 2012
Four-channel asymmetric Real-Time PCR hybridization probe assay: a rapid pre-screening method for critical BCR-ABL kinase domain mutationsJordi Martinez-Serra, Antonio Gutiérrez, Toni F Marcús, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phaseTimothy Hughes, Giuseppe Saglio, Susan Branford, et al.
Leukemia & Lymphoma|November 6, 2012
Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms WorkshopRichard A Van Etten, Michael Mauro, Jerald P Radich, et al.
Haematologica|January 19, 2007
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working PartyGianantonio Rosti, Ilaria Iacobucci, Simona Bassi, et al.
Oncotarget|March 17, 2016
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patientsSimona Soverini, Caterina De Benedittis, Katerina Machova Polakova, et al.
Clinical and Translational Medicine|April 25, 2025
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid LeukemiaManuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 25, 2024
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National NetworkMassimo Breccia, Rosalba Cucci, Giovanni Marsili, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular responseFrancesca Palandri, Ilaria Iacobucci, Simona Soverini, et al.
Leukemia Research|January 14, 2015
The impact of sensitive KIT D816V detection on recognition of indolent Systemic MastocytosisGiovanna De Matteis, Roberta Zanotti, Sabrina Colarossi, et al.
Hematological Oncology|May 8, 2021
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplantCristina Papayannidis, Chiara Sartor, Alida Dominietto, et al.
Pageof 17